Safety and efficacy of tafasitamab with or without lenalidomide
... added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study
Recent publication
The phase 1b study of tafasitamab, published open access in the journal Blood, primarily evaluated the safety of the anti-CD19 immunotherapeutic. The study involved 66 patients with relapsed/refractory diffuse large B-cell lymphoma, including patients from University Hospital St. Pölten. While one group received tafasitamab in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone in 6 cycles, the other group received the same first-line therapy plus lenalidomide. In addition to side effects, the doctors also analysed the effectiveness of the drug combinations. Based on the results, a phase 3 trial will follow to investigate the potential benefit of adding tafasitamab and lenalidomide.
Belada D, Kopeckova K, Bergua burgues JM, Stevens D, André M, Persona EP et al. Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study. Blood. 2023 Oct 19;142(16):1348-1358. doi: 10.1182/blood.2023020637
Dr. Petra Pichler
Division of Internal Medicine 1 (University Hospital St. Pölten)
